Ivy Institute of Stem Cells

Ivy Institute of Stem Cells is a biotechnology company based in Beijing, China, specializing in the development of regenerative medicine therapies using human umbilical cord-derived mesenchymal stem cells (UC-MSCs). The company focuses on treating severe and life-threatening conditions, particularly in the fields of pulmonology, gastroenterology, and cardiology. Its clinical pipeline includes programs for Acute Respiratory Distress Syndrome (ARDS), paraquat poisoning-induced lung injury, active ulcerative colitis, and chronic myocardial ischemia. Ivy Institute of Stem Cells operates the 307-Ivy Translational Medicine Center in collaboration with the Affiliated Hospital to the Academy of Military Medical Sciences to advance its cell therapy candidates through clinical development.